Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... Exciting new work by a Florida State University ... that can take your temperature, emit white light, and ... the molecule looks like a butterfly. , Biwu Ma, ... Engineering in the FAMU-FSU College of Engineering, created the ... has continued to discover that his creation has many ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... is offering a promotion for Eppendorf Safe ... customers to purchase the highest quality tubes at ... are ideal for customers doing chemical, medical, pharmaceutical, ... technicians who are not regularly able to afford ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- ... CBPO) (,China Biologic, or the,Company,), one ... in the,People,s Republic of China (,PRC,), ... subsidiary, Shandong Taibang Biological Products Co.,Ltd. ...
... -- Tianyin,Pharmaceutical, Co., Inc., (NYSE: TPI ), ... based in Chengdu, China, today,announced that management will hold ... at 8:45 a.m. EST on Wednesday, February 18, 2009.,Financial ... the market,closes. , Interested parties ...
... China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ... and markets specialty pharmaceutical products in China,announced today ... the generic,version of the leading hypertension drug Candesartan. ... for this product are anticipated to require,approximately 18 ...
Cached Biology Technology:China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST 2China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan 2China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan 3
(Date:9/1/2014)... 50 years ago, electron microscopy revealed the presence of ... and disappear. But scientists still don,t know what they ... proteins are believed to be crucial to the life ... approach to disease treatment., In the Journal of ... to investigators from various backgrounds, from biophysics to cell ...
(Date:8/31/2014)... of Warwick have discovered that ,good, cholesterol is turned ... methylglyoxal - MG, was found to damage ,good, HDL ... the body. , Low levels of HDL, High ... increased levels of MG being common in the elderly ... Supported by funding from the British Heart Foundation (BHF) ...
(Date:8/31/2014)... is developing drugs that are highly effective against a ... patient. Such properties are directly related to the 3D ... have a shape that is perfectly complementary to a ... specificity. Publishing in Nature Chemistry , EPFL scientists ... the 3D structure of bioactive peptides and enhance their ...
Breaking Biology News(10 mins):Scientists call for investigation of mysterious cloud-like collections in cells 2Sugar substance 'kills' good HDL cholesterol, new research finds 2A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3
... director of Syracuse Biomaterials Institute (SBI) and Milton and ... Syracuse University,s L.C. Smith College of Engineering and Computer ... functionally graded materials (FGMs) to shape memory polymers (SMPs). ... switch between two shapes, from a fixed (temporary) shape ...
... SPRING HARBOR, N.Y. (Jan. 5, 2011) Auxin is a ... aspects of plant development and physiology. A new book, ... overview of auxin and its many roles in plant biology. ... plant research," write the editors, Mark Estelle, Dolf Weijers, Karin Ljung, ...
... Treating fractures in children requires special knowledge of ... and adolescent patients is less often caused by technical ... in this age group. Using the example of treating ... Marburg-Gieen University Medical Center, and Lucas Wessel, University Medical ...
Cached Biology News:Syracuse University team develops functionally graded shape memory polymers 2
... The Rapid-Screen cDNA Library Panels were ... just three sets of PCRs to identify ... analysis is performed in a 96-well "Master ... from 5,000 clones. Having identified the positive ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... is an affordable, compact benchtop imager ... providing a broad array of automated ... high-resolution images with high-performance laser autofocus, ... and emission filter changers, and a ...
... Contents include: Microarray hybridization chamber ... chamber top, clamp, thumbscrew) Microarray chamber user ... and are intended to be cleaned and ... with Agilents Catalog Oligo Microarray kits and ...
Biology Products: